

# Gaston De Serres

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3157851/publications.pdf>

Version: 2024-02-01

57  
papers

2,039  
citations

331670

21  
h-index

254184

43  
g-index

62  
all docs

62  
docs citations

62  
times ranked

2781  
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistence of infectivity in elderly individuals diagnosed with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection 10 days after onset of symptoms: A cross-sectional study. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 659-662.	1.8	3
2	Characterization and evolution of infection control practices among severe acute respiratory coronavirus virus 2 (SARS-CoV-2)â€“infected healthcare workers in acute-care hospitals and long-term care facilities in QuÃ©bec, Canada, Spring 2020. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 481-489.	1.8	9
3	Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From QuÃ©bec, Canada. <i>Clinical Infectious Diseases</i> , 2022, 75, e805-e813.	5.8	26
4	Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 102-104.	1.8	10
5	Physician vaccination practices in mild to moderate inborn errors of immunity and retrospective review of vaccine completeness in IEI: results from the Canadian Immunization Research Network. <i>Allergy, Asthma and Clinical Immunology</i> , 2022, 18, 32.	2.0	0
6	Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. <i>Clinical Infectious Diseases</i> , 2022, 75, 1980-1992.	5.8	92
7	Persisting chemosensory impairments in 366 healthcare workers following COVID-19: an 11-month follow-up. <i>Chemical Senses</i> , 2022, 47, .	2.0	6
8	Exposure to <i>Toxoplasma gondii</i> Through Consumption of Raw or Undercooked Meat: A Systematic Review and Meta-Analysis. <i>Vector-Borne and Zoonotic Diseases</i> , 2021, 21, 40-49.	1.5	12
9	Chemosensory Dysfunctions Induced by COVID-19 Can Persist up to 7 Months: A Study of Over 700 Healthcare Workers. <i>Chemical Senses</i> , 2021, 46, .	2.0	24
10	Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent. <i>Vaccine</i> , 2020, 38, 715-718.	3.8	10
11	Children vaccination coverage surveys: Impact of multiple sources of information and multiple contact attempts. <i>Vaccine</i> , 2020, 38, 1202-1210.	3.8	3
12	Investigating the association of receipt of seasonal influenza vaccine with occurrence of anesthesia/paresthesia and severe headaches, Canada 2012/13â€“2016/17, the Canadian Vaccine Safety Network. <i>Vaccine</i> , 2020, 38, 3582-3590.	3.8	5
13	Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2020, 20, 251.	2.9	14
14	Nephrotic syndrome following four-component meningococcal B vaccination: Epidemiologic investigation of a surveillance signal. <i>Vaccine</i> , 2019, 37, 4996-5002.	3.8	12
15	A mixed vaccination schedule of HPV vaccine induces a 100% seropositivity to all 9 HPV types included in 9vHPV vaccine. <i>Vaccine</i> , 2019, 37, 4422-4423.	3.8	1
16	Assessment of naturally acquired neutralizing antibodies against rabies Lyssavirus in a subset of Nunavikâ€™s Inuit population considered most at risk of being exposed to rabid animals. <i>Zoonoses and Public Health</i> , 2019, 66, 533-539.	2.2	5
17	Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. <i>Vaccine</i> , 2019, 37, 4243-4245.	3.8	47
18	Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials. <i>BMJ Open</i> , 2019, 9, e026953.	1.9	16

#	ARTICLE	IF	CITATIONS
19	Rate of Recurrence of Adverse Events Following Immunization. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 377-383.	2.0	8
20	Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine. <i>Expert Review of Vaccines</i> , 2018, 17, 99-102.	4.4	18
21	Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. <i>Vaccine</i> , 2018, 36, 8039-8046.	3.8	21
22	Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age. <i>Vaccine</i> , 2018, 36, 6688-6694. <sup>3.8</sup>	3.8	7
23	Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine – A randomized clinical trial. <i>Vaccine</i> , 2018, 36, 7017-7024.	3.8	24
24	Impact of the addition of new vaccines in the early childhood schedule on vaccine coverage by 24 months of age from 2006 to 2016 in Quebec, Canada. <i>Vaccine</i> , 2018, 36, 4383-4391.	3.8	1
25	Post-immunisation fever and the antibody response to measles-containing vaccines. <i>Epidemiology and Infection</i> , 2018, 146, 1584-1592.	2.1	7
26	Reduced Antibody Response to Infant Measles Vaccination: Effects Based on Type and Timing of the First Vaccine Dose Persist After the Second Dose. <i>Clinical Infectious Diseases</i> , 2017, 65, 1094-1102.	5.8	24
27	Clinical Approach Used in Medical Consultations for Allergic-Like Events Following Immunization: Case Series Report in Relation to Practice Guidelines. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 718-727.e1.	3.8	14
28	Risk of Recurrence of Adverse Events Following Immunization: A Systematic Review. <i>Pediatrics</i> , 2017, 140, e20163707.	2.1	20
29	Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement. <i>PLoS ONE</i> , 2017, 12, e0163586.	2.5	49
30	Prevalence of risk factors for acquiring measles during the 2011 outbreak in Quebec and impact of the province-wide school-based vaccination campaign on population immunity. <i>PLoS ONE</i> , 2017, 12, e0186070.	2.5	1
31	Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. <i>Vaccine</i> , 2016, 34, 2053-2054.	3.8	8
32	Measles in Canada Between 2002 and 2013. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv048.	0.9	15
33	Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. <i>Vaccine</i> , 2015, 33, 2684-2689.	3.8	101
34	Dramatic reduction in hepatitis B through school-based immunization without a routine infant program in a low endemicity region. <i>BMC Infectious Diseases</i> , 2015, 15, 227.	2.9	3
35	Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors. <i>Vaccine</i> , 2015, 33, 4464-4471.	3.8	9
36	Canadian vaccine research networks: Vaccine safety resources for Canada. <i>Canada Communicable Disease Report</i> , 2015, 41, 18-23.	1.3	4

#	ARTICLE	IF	CITATIONS
37	Low 2012â€“13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses. PLoS ONE, 2014, 9, e92153.	2.5	347
38	Other Respiratory Viruses Are Important Contributors to Adult Respiratory Hospitalizations and Mortality Even During Peak Weeks of the Influenza Season. Open Forum Infectious Diseases, 2014, 1, ofu086.	0.9	45
39	Selection bias in the comparison between adjuvanted and unadjuvanted influenza vaccine effectiveness. Vaccine, 2014, 32, 6596.	3.8	4
40	Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis. Pediatrics, 2014, 134, e983-e991.	2.1	14
41	Randomized Controlled Ferret Study to Assess the Direct Impact of 2008â€“09 Trivalent Inactivated Influenza Vaccine on A(H1N1)pdm09 Disease Risk. PLoS ONE, 2014, 9, e86555.	2.5	19
42	Canadian paediatricians' approaches to managing patients with adverse events following immunization: The role of the Special Immunization Clinic network. Paediatrics and Child Health, 2014, 19, 310-4.	0.6	3
43	Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. Vaccine, 2013, 31, 5989-5996.	3.8	29
44	Largest Measles Epidemic in North America in a Decadeâ€“Quebec, Canada, 2011: Contribution of Susceptibility, Serendipity, and Superspreading Events. Journal of Infectious Diseases, 2013, 207, 990-998.	4.0	93
45	Measles in Children Vaccinated With 2 Doses of MMR. Pediatrics, 2013, 132, e1126-e1133.	2.1	31
46	The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Eurosurveillance, 2013, 18, .	7.0	192
47	Virus-host interactions and the unusual age and sex distribution of human cases of influenza A(H7N9) in China, April 2013. Eurosurveillance, 2013, 18, .	7.0	23
48	Higher Risk of Measles When the First Dose of a 2-Dose Schedule of Measles Vaccine Is Given at 12â€“14 Months Versus 15 Months of Age. Clinical Infectious Diseases, 2012, 55, 394-402.	5.8	72
49	Risk of Guillain-BarrÃ© Syndrome Following H1N1 Influenza Vaccination in Quebec. JAMA - Journal of the American Medical Association, 2012, 308, 175-81.	7.4	74
50	Allergic symptoms after pandemic influenza vaccination rarely mediated by vaccine-specific IgE. Journal of Allergy and Clinical Immunology, 2012, 130, 1423-1426.	2.9	17
51	Recurrence Risk of Oculorespiratory Syndrome After Influenza Vaccination. Archives of Internal Medicine, 2004, 164, 2266.	3.8	23
52	Safety of revaccination of patients affected by the oculo-respiratory syndrome (ORS) following influenza vaccination. Canada Communicable Disease Report, 2004, 30, 9-16.	1.3	3
53	Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Rate of Recurrence of Oculorespiratory Syndrome Following Influenza Vaccination among Persons Previously Affected. Clinical Infectious Diseases, 2003, 37, 1059-1066.	5.8	24
54	Skin testing to evaluate oculo-respiratory syndrome (ORS) associated with influenza vaccination during the 2000â€“2001 season. Vaccine, 2002, 20, 2713-2719.	3.8	16

#	ARTICLE	IF	CITATIONS
55	Morbidity of Pertussis in Adolescents and Adults. <i>Journal of Infectious Diseases</i> , 2000, 182, 174-179.	4.0	298
56	Protection after Two Doses of Measles Vaccine Is Independent of Interval between Doses. <i>Journal of Infectious Diseases</i> , 1999, 180, 187-190.	4.0	21
57	Measles vaccine efficacy during an outbreak in a highly vaccinated population: Incremental increase in protection with age at vaccination up to 18 months. <i>Epidemiology and Infection</i> , 1995, 115, 315-323.	2.1	39